European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine Feb 14, 2025 08:30AM
European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine Feb 14, 2025 08:00AM
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) Feb 13, 2025 07:00AM
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B Feb 7, 2025 09:12AM
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) Dec 13, 2024 10:38AM
View Older Stories

Dec 9, 2024 08:00AM CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
Oct 16, 2024 09:00AM CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
Oct 4, 2024 12:30PM CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
Oct 1, 2024 11:00AM CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
Sep 30, 2024 08:00AM Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Sep 25, 2024 04:30PM CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Sep 17, 2024 11:30AM Mark Cuban Foundation and CSL Bring Free AI Bootcamp to Philadelphia Teens
Sep 13, 2024 08:15AM Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Me
Sep 13, 2024 08:00AM Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b
Jul 9, 2024 09:00AM CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season
May 30, 2024 09:00AM CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza
May 20, 2024 08:30AM Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024 08:30AM Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
May 7, 2024 04:00PM Ligand Reports First Quarter 2024 Financial Results
May 2, 2024 09:30AM Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
Apr 30, 2024 12:19PM Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
Mar 6, 2024 09:00AM CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
Feb 11, 2024 05:47PM CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Feb 5, 2024 08:30AM New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Jan 16, 2024 08:00AM Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
Jan 3, 2024 08:00AM CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
Jan 2, 2024 08:00AM CSL Behring Demonstrates Continued Commitment to Alpha-1 Community with Addition of ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-Gram Vials
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 21, 2023 08:00AM CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Dec 14, 2023 02:47PM CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
Dec 11, 2023 07:30PM CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People L
Nov 28, 2023 08:06AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' (ARCT) ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:05AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Nov 28, 2023 08:00AM Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
Nov 24, 2023 02:00AM Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Oct 27, 2023 10:00AM CSL and uniQure Win 2023 Prix Galien USA Award
Oct 11, 2023 08:30AM New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
Sep 19, 2023 04:50AM CSL Seqirus Presents Real-World Evidence at ESWI Demonstrating the Impact of Influenza Vaccination Campaigns to Help Protect People and Healthcare Systems
Sep 5, 2023 08:30AM Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
Aug 28, 2023 08:30AM CSL Seqirus Announces Third U.S. Government Award in Relation to Influenza A(H5N8) Candidate Vaccine
Aug 17, 2023 07:08AM CSL Appoints Jeffrey Ball as First Chief Sustainability Officer
Jul 17, 2023 08:30AM CSL Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2023/24 U.S. Season
Jun 20, 2023 07:00AM CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
May 18, 2023 02:00AM Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
Apr 18, 2023 09:00AM CSL Behring Receives FDA Approval for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 50mL Prefilled Syringe
Mar 27, 2023 03:30PM CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts
Mar 1, 2023 08:00AM The Lancet Publishes Pivotal Phase 3 Data on CSL's First-in-Class Garadacimab for HAE
Feb 28, 2023 08:00AM Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
Feb 26, 2023 10:45AM CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Feb 23, 2023 08:00AM CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)
Feb 21, 2023 08:00AM Biotech Leader CSL Again Named Among America's Best Employers by Forbes
Feb 20, 2023 04:42PM First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
Jan 10, 2023 08:00AM Ten Emerging Rare Disease Scientists Score Research Grants Totaling $200,000 From Uplifting Athletes
Jan 5, 2023 08:00AM SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
Dec 12, 2022 05:46PM CSL Announces Next CEO & Managing Director
View Older Stories